HLE Glascoat Ltd
Q1 FY25 Earnings Call Analysis
Industrial Manufacturing
fundraise: No informationcapex: Norevenue: Category 3margin: Category 3orderbook: Yes
💰fundraise
Any current/future new fundraising through debt or equity?
- The company does not have any large CAPEX planned for the current year, which usually correlates with the need for major fundraising.
- No specific mention of new fundraising through debt or equity was made during the call.
- The company has repaid approximately Rs. 50 crores of debt in the financial year, indicating focus on debt reduction rather than new borrowing.
- The management emphasized maintaining a disciplined financial approach and conserving resources for growth but did not indicate plans for fresh equity or debt raising.
- Maintenance CAPEX is modest (Rs. 12-15 crores annually), manageable within existing cash flows.
- Overall, no indication of planned new debt or equity fundraising at present or in the near future was provided.
🏗️capex
Any current/future capex/capital investment/strategic investment?
- No major CAPEX is currently planned for any of HLE Glascoat's plants, including the Anand facility. The focus is on minimal maintenance CAPEX, estimated between Rs. 12 to 15 crores annually across five plants (India and Germany).
- The company does not foresee large short-term CAPEX but is working near 75% capacity utilization, indicating room for growth without heavy capital expenditure.
- Strategic investment includes the ongoing proposed amalgamation with Kinam Enterprise, to be finalized in July 2025, expected to unlock operational synergies and expand market reach.
- Kinam Engineering has started supplying a large oil & gas order, marking a strategic entry into this vertical, expected to be executed fully in Q1 FY 25-26.
- Investments are also directed toward process automation and sustainable designs, exemplified by the new Center of Excellence at Anand, Gujarat, aiding productivity and ESG goals.
- Overall, growth is expected through organic capacity use and strategic acquisitions rather than large new CAPEX projects.
📊revenue
Future growth expectations in sales/revenue/volumes?
- Thaletec standalone growth expected at around 15% for the coming year with EBITDA margin of 14-15%.
- Overall business growth guidance in the high teens, approximately 16% to 20%.
- Glass-lined equipment business showed 17% growth in FY '25; expected to continue benefiting from pharma sector.
- Heat transfer equipment business grew 38% in FY '25, contributing Rs. 122 crores, expected to grow with large projects.
- Filtration, drying (F&D) business had a subdued FY '25 but has a strong order book and is expected to recover revenues with over six months visibility.
- Kinam business expected to cross Rs. 200 crores in FY '26 with margin maintenance and disproportionate growth.
- Growth driven primarily by pharma sector with expected revival in other chemical industry segments.
- Market share gains anticipated through new products and stronger customer engagement.
📈margin
Future growth expectations in earnings/operating earnings/profits/EPS?
- The company expects overall revenue growth in the high teens, specifically between 16% to 20%, driven primarily by the pharma sector and recovery in chemical industries.
- Thaletec standalone business is projected to grow around 15% with EBITDA margins in the 14%-15% range.
- Kinam unit is expected to cross Rs. 200 crores revenue by FY ‘26, with sustained margin trajectory.
- EBITDA margins are anticipated to be sustainable in the 17%-18% range for India business and 14%-15% for German business.
- The company aims to achieve the milestone of Rs. 100 crore net profit soon.
- Strong operational performance in Q4 FY ‘25 resulted in an EBITDA margin of 15.3% and PAT margin of 9.5%, indicating improving profitability.
- No major CAPEX planned; growth expected through existing capacity with minimal maintenance CAPEX.
- Order book visibility is around 6-7 months, supporting revenue growth visibility.
📋orderbook
Current/ Expected Orderbook/ Pending Orders?
- As of March 31, 2024, the repeated order book stood at Rs. 575.1 crores.
- Since then, even after accounting for sales, the order book has increased by about Rs. 100 crores.
- This provides roughly six months of visibility on orders for the India business and about seven months for the international business.
- The majority of the orders in the Rs. 575 crore order book are from the pharmaceutical industry.
- Regarding the large order from Kinam Enterprise in oil and gas, the size is approximately Rs. 60 crores, with about 25% supplied so far.
- The company expects to execute these orders without needing major new CAPEX, relying mostly on maintenance CAPEX between Rs. 12-15 crores annually across all plants.
- Growth guidance linked to order execution is estimated at around 16% to 20% overall.
